Market Performance
- SK Biopharmaceuticals (326030.KS)
- Close: KRW 76,900 (↓ 0.13 % at 06:32 PM Central Europe, Friday 23 Feb).
- 24‑hour volume: KRW 12.7 billion.
- Shares outstanding: 78.4 million.
- Market capitalization: KRW 5.9 trillion.
- Year‑to‑date change: ↓ 1.32 % since the end of the previous month.
- 200‑day simple moving average: KRW 94,856.5.
- 52‑week high/low: KRW 144,100 (28 Nov 2025) / KRW 67,800 (15 Oct 2026).
Comparative Stock Activity (Last 24 Hours)
| Ticker | 24‑hr change | Current price | Market cap | P/E |
|---|---|---|---|---|
| Lg Cns (064400.KS) | +0.83 % | KRW 72,800 | KRW 7 trillion | 13.31 |
| Lg Uplus (032640.KS) | –2.63 % | KRW 14,160 | KRW 6.3 trillion | 11.69 |
| Isupetasys (007660.KS) | –5.74 % | KRW 87,000 | KRW 7 trillion | 36.32 |
| Kiwoom Securities (039490.KS) | –3.13 % | KRW 214,500 | KRW 5.9 trillion | 3.4 |
Kiwoom Securities Commentary
Kiwoom Securities analysts highlighted that SK Hynix’s decision to suspend the review of a U.S. initial public offering for its Solidigm subsidiary has contributed to sector‑wide volatility. The pause is intended to reassess the timing and scale of capital‑raising, reflecting broader market conditions. Analysts note that the suspension may stabilize investor sentiment amid mixed signals from U.S. technology earnings and concerns over debt in AI‑related businesses. Additionally, Kiwoom’s platform recorded notable retail interest in the second‑day performance of Korean neocloud provider Elice, whose shares have remained near IPO levels following an initial decline. This activity signals ongoing caution among equity investors as they evaluate the sustainability of AI infrastructure funding against a broader risk‑off backdrop.
Company Overview
SK Biopharmaceuticals Co Ltd. is headquartered in Seoul, South Korea. The company focuses on developing biotechnologies and therapeutic agents for infectious diseases, cancer, neurological disorders, and related conditions. It aims to deliver high‑quality, reliable, and accessible healthcare solutions to improve patient outcomes and quality of life.
